Literature DB >> 2655685

Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension.

Y Lacourcière1, P Provencher.   

Abstract

1. Thirty-eight patients with mild to moderate essential hypertension (seated diastolic 95-110 mm Hg) were randomized double-blind to treatment with either zofenopril (n = 19) or hydrochlorothiazide (n = 19) over a period of 12 weeks. 2. Office blood pressure, heart rate, side effects and metabolic changes were assessed at the end of the run-in period on placebo and after 4, 8, 12 weeks treatment at the same time, 22-24 h after the last dosing. Ambulatory recordings over 14 h (8 h to 22 h) were performed at the end of placebo period and after active treatment for 12 weeks. 3. The two regimes reduced office blood pressures equally with minimal additional effect seen on increasing the dose. Both zofenopril and hydrochlorothiazide lowered average baseline ambulatory blood pressure, but zofenopril had greater efficacy in reducing BP during some working hours. 4. Adverse reactions were mild and transient with both drugs. There were no significant changes in laboratory values. 5. Thus hydrochlorothiazide and zofenopril given once daily at low dosage both reduce office and ambulatory blood pressures and are well tolerated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655685      PMCID: PMC1379837          DOI: 10.1111/j.1365-2125.1989.tb05379.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension.

Authors:  G Parati; G Pomidossi; F Albini; D Malaspina; G Mancia
Journal:  J Hypertens       Date:  1987-02       Impact factor: 4.844

2.  Benefits of low vs high dosages of diuretics.

Authors:  N M Kaplan
Journal:  Clin Ther       Date:  1984       Impact factor: 3.393

3.  Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress.

Authors:  R B Devereux; T G Pickering; G A Harshfield; H D Kleinert; L Denby; L Clark; D Pregibon; M Jason; B Kleiner; J S Borer; J H Laragh
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

4.  The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide.

Authors:  G McVeigh; D Galloway; D Johnston
Journal:  BMJ       Date:  1988-07-09

5.  The future of angiotensin-converting enzyme inhibitors.

Authors:  G B Mackaness
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

6.  Efficacy of low dose captopril once daily in diuretic resistant hypertension.

Authors:  P Baumgart; W Tenschert; H Vetter
Journal:  Postgrad Med J       Date:  1986       Impact factor: 2.401

7.  Low dose captopril twice daily lowers blood pressure without disturbance of the normal circadian rhythm.

Authors:  J L Meijer; H G Ardesch; J C van Rooijen; J H de Bruijn
Journal:  Postgrad Med J       Date:  1986       Impact factor: 2.401

8.  Effects of enalapril, a new converting enzyme inhibitor, in hypertension.

Authors:  R K Ferguson; P H Vlasses; B N Swanson; P Mojaverian; M Hichens; J D Irvin; P B Huber
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

9.  The prognostic value of ambulatory blood pressures.

Authors:  D Perloff; M Sokolow; R Cowan
Journal:  JAMA       Date:  1983-05-27       Impact factor: 56.272

10.  What is the role of ambulatory blood pressure monitoring in the management of hypertensive patients?

Authors:  T G Pickering; G A Harshfield; R B Devereux; J H Laragh
Journal:  Hypertension       Date:  1985 Mar-Apr       Impact factor: 10.190

  10 in total
  9 in total

Review 1.  Diuretics as a basis of antihypertensive therapy. An overview.

Authors:  N M Kaplan
Journal:  Drugs       Date:  2000       Impact factor: 9.546

2.  Once vs twice daily administration of a fixed combination of captopril plus hydrochlorothiazide in essential hypertension: a double-blind crossover study in known responders to a standard combination.

Authors:  Y Lacourcière; L Poirier; P Provencher; P H Guivarc'h
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 3.  Torasemide in comparison with thiazides in the treatment of hypertension.

Authors:  P Baumgart
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

4.  The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recording.

Authors:  R J MacFadyen; A D Bainbridge; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

5.  Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients : A Randomised, Double-Blind, Multicentre Study.

Authors:  Ettore Malacco; Simona Piazza; Stefano Omboni
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

6.  Antihypertensive effect of zofenopril plus hydrochlorothiazide versus zofenopril monotherapy in patients with essential hypertension according to their cardiovascular risk level: A post hoc analysis.

Authors:  Ettore Malacco; Stefano Omboni
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

7.  Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.

Authors:  Enrico Agabiti-Rosei; Athanasios Manolis; Dario Zava; Stefano Omboni
Journal:  Adv Ther       Date:  2014-01-11       Impact factor: 3.845

Review 8.  Roles of Hydrogen Sulfide Donors in Common Kidney Diseases.

Authors:  Ebenezeri Erasto Ngowi; Muhammad Sarfraz; Attia Afzal; Nazeer Hussain Khan; Saadullah Khattak; Xin Zhang; Tao Li; Shao-Feng Duan; Xin-Ying Ji; Dong-Dong Wu
Journal:  Front Pharmacol       Date:  2020-11-19       Impact factor: 5.810

9.  Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial.

Authors:  Ettore Malacco; Stefano Omboni; Gianfranco Parati
Journal:  Int J Hypertens       Date:  2015-08-05       Impact factor: 2.420

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.